NEW YORK, October 12, 2016 /PRNewswire/ --
US markets went back to a bearish environment following Monday's bullish performance. On Tuesday, the NASDAQ Composite ended the trading session down 1.54%; the Dow Jones Industrial Average lost 1.09%; and the S&P 500 closed down 1.24%. Following the market trends, Stock-Callers.com looks at the performance of the following Biotech stocks: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), PDL BioPharma Inc. (NASDAQ: PDLI), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Cara Therapeutics Inc. (NASDAQ: CARA). Learn more about these stocks by accessing their free research reports at:
New Haven, Connecticut headquartered Alexion Pharmaceuticals Inc.'s stock declined 3.40%, to close the day at $121.77. The stock recorded a trading volume of 1.45 million shares, which is on par with its three months average volume. Shares of the Company, which develops and commercializes life-transforming therapeutic products, are trading 12.94% below its 200-day moving average. Additionally, the stock traded at a PE ratio of 308.28 and has a Relative Strength Index (RSI) of 42.07.
On September 23rd, 2016, research firm Wedbush initiated a 'Neutral' rating on the Company's stock, issuing a target price of $132 per share. Free research report on ALXN is available at:
On Tuesday, shares in Incline Village, Nevada headquartered PDL BioPharma Inc. ended the session 3.24% lower at $3.29 with a total volume of 554,760 shares traded. Shares of PDL BioPharma, which manages a portfolio of patents and royalty assets in the US and Europe, have gained 10.77% in the past one month. The stock is trading 5.82% and 3.21% above its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company traded at a PE ratio of 2.35 and have an RSI of 54.09. The complimentary research report on PDLI can be downloaded at:
On Tuesday, shares in Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc. recorded a trading volume of 446,031 shares. The stock ended the day 4.24% lower at $4.29. Shares of BioCryst Pharmaceuticals, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have surged 47.42% in the last three months. The Company is trading above its 200-day moving average by 6.62%. Furthermore, shares of BioCryst Pharmaceuticals have an RSI of 40.50. Visit us today and access our complete research report on BCRX at:
Shelton, Connecticut headquartered Cara Therapeutics Inc.'s stock declined 6.42%, to finish Tuesday's session at $8.16 with a total volume of 1.31 million shares traded. Over the last one month and the previous three months, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, have surged 35.77% and 61.26%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 22.95% and 15.64%, respectively. Cara Therapeutics' stock has an RSI of 55.32. Get free access to your research report on CARA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA